Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

CONTEXT: Lenvatinib improved the progression-free survival (PFS) and overall response rate of patients with radioiodine-refractory differentiated thyroid cancer vs placebo in the Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT). OBJECTIVE: The objective of the stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Endocrinol Metab
Principais autores: Robinson, Bruce, Schlumberger, Martin, Wirth, Lori J., Dutcus, Corina E., Song, James, Taylor, Matthew H., Kim, Sung-Bae, Krzyzanowska, Monika K., Capdevila, Jaume, Sherman, Steven I., Tahara, Makoto
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5095235/
https://ncbi.nlm.nih.gov/pubmed/27548104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-3989
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados